On March 19, 2026 Globant (NYSE: GLOB), a digitally native company that helps organizations thrive in a digital and AI-powered future, and PharmaMar, world leader in the discovery, development and commercialization of marine-derived anti-cancer drugs, reported a new collaboration designed to speed up cancer drug discovery through artificial intelligence.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Through Globant Enterprise AI, the two organizations have created a multi-agent AI system that delivers more than 90% accuracy in complex data retrieval and reduces time to insights up to 15-fold, helping scientists select high-potential drug candidates for clinical development in a fraction of the time previously required.

The platform is capable of analyzing large volumes of scientific, regulatory, and clinical data sources to assist with decision-making across PharmaMar’s R&D ecosystem and enable continuous, self-improving workflows.

Over 20 specialized digital agents are working across preclinical, clinical, regulatory, commercial and strategy areas, uniting human creativity and machine precision in the fight against cancer. Each agent collaborates within GEAI’s secure architecture to process documents, simulate scenarios, and rank the most promising pharmaceutical assets.

The system enables reviews of over 4,500 research documents to prioritize the 10 most viable treatment-indication combinations out of over 8,000 possibilities – work that would have taken months for human researchers to complete.

This intelligent system integrates information from internal databases, scientific publications, and global regulatory sources such as the FDA and EMA, allowing PharmaMar’s teams to identify promising treatment combinations and make more informed, faster decisions.

"Drug discovery has always been a race against time, and in oncology, that time can mean everything," said Dr. Javier Jimenez, Chief Medical Officer at PharmaMar." By integrating Globant’s AI technologies, we can process data from thousands of documents in seconds, simulate scenarios, and focus our research efforts where they have the highest potential to make a difference for patients."

Beyond speed and efficiency, the collaboration strengthens PharmaMar’s ability to reuse institutional knowledge and fosters a new culture of digital innovation across its teams. In the next phase of the project, PharmaMar plans to extend these capabilities to enable hypothesis generation, real-time compliance checks, and automated content creation for scientific reporting.

"PharmaMar’s vision proves what’s possible when human intelligence and AI systems work side by side," said Ariel Capone, CEO of Globant’s Healthcare and Life Sciences AI Studio. "By leveraging agentic AI, we’re building a new model for drug discovery; one that brings precision and scalability to a field that directly impacts millions of lives."

(Press release, PharmaMar, MAR 19, 2026, View Source [SID1234663778])

On March 19, 2026 Kaida BioPharma, a biotechnology company developing targeted therapies for women with hard-to-treat gynecologic cancers, reported its executive leadership team and board. Each member brings decades of experience in biotechnology, clinical development, regulatory strategy, manufacturing, finance, and commercialization to help advance Kaida’s lead product candidate, KAD-101, toward first-in-human clinical evaluation. The company is developing KAD-101 for recurrent ovarian cancer, where treatment options narrow quickly and durable control remains limited.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Kaida BioPharma is building KAD-101, a next-generation prolactin receptor antagonist for the ovarian cancer gap, the space where patients are too often left cycling through treatment with too few durable options.

In addition to her role as Chairperson of the Board, Kaida founder Dr. Stella Vnook has been named Acting Chief Executive Officer. Dr. Vnook is an accomplished biotechnology founder, executive, and advisor with extensive experience guiding early-stage therapeutics from scientific foundation through capital formation. At Kaida, she leads corporate strategy, development planning, and investor engagement.

"The science brought me here, and the women out there still fighting are why I stay. At Kaida, we are building for the ovarian cancer gap, for patients whose options narrow too fast and whose disease still outpaces available therapies," said Dr. Vnook. "By targeting the survival signals that keep these tumors alive, we believe KAD-101 has the potential to help overcome treatment resistance and create a new path toward more durable control. More options mean more time, and more time means everything."

Craig Pierson, a founder alongside Dr. Vnook, has been appointed Director at Kaida BioPharma. Mr. Pierson is a life sciences investor and company builder with more than 25 years of experience in investment banking and private capital formation. He provides strategic oversight and financing expertise.

George E. Peoples, MD, FACS has been appointed fractional Chief Medical Officer. Dr. Peoples is a surgical oncologist with decades of experience in translational oncology and clinical development. He is also the founder of the Cancer Vaccine Development Program, Cancer Insight, and LumaBridge. At Kaida, he helps guide clinical strategy and IND planning.

John Langenheim, PhD has been appointed fractional Chief Scientific Officer. Dr. Langenheim is a molecular biologist with more than 20 years of experience in therapeutic protein design and preclinical development. His scientific leadership has been instrumental in advancing KAD-101 toward clinical evaluation.

Pamela Swiggard has been appointed Head of Regulatory Affairs. She is a pharmaceutical executive with prior experience at companies including Pfizer and Endo Pharmaceuticals. She brings deep expertise across the product lifecycle, from development through regulatory approval and commercialization. At Kaida, she leads regulatory strategy and FDA engagement in support of IND readiness for KAD-101.

Eric Hacherl, PhD has been appointed Head of Manufacturing. Dr. Hacherl is a senior pharmaceutical operations leader with more than 25 years of experience in biologics manufacturing, cGMP compliance, and process development. At Kaida, he is responsible for helping ensure clinical supply readiness for KAD-101.

Mark Booth has been appointed Chief Commercial Officer. Mr. Booth is a seasoned pharmaceutical and biotechnology executive with more than 25 years of experience building commercial strategies for oncology and rare disease products. His background includes leadership across launch planning, brand strategy, access, and market development for important oncology products, including EMEND, EMEND IV, Zolinza, vintafolide, KEYTRUDA, and the avutometinib plus defactinib combination for low grade serous ovarian cancer. At Kaida, he is responsible for commercial strategy for KAD-101, including positioning, market development, and long-term access planning.

(Press release, Kaida BioPharma, MAR 19, 2026, View Source [SID1234663777])

On March 19, 2026 Context Therapeutics Inc. ("Context" or the "Company") (Nasdaq: CNTX), a clinical-stage biopharmaceutical company advancing T cell engaging ("TCE") bispecific antibodies for solid tumors, reported a poster presentation at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting 2026, taking place April 17-22, 2026 in San Diego, CA. The presentation will highlight preclinical data regarding the Company’s asset, CT-202, a Nectin-4 x CD3 TCE.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Poster Presentation Details:
Title: Targeting solid tumors with pH-dependent dual-specific TCEs: First-in-human development of CT-202
Abstract Number: 5392
Date and Time: Tuesday, April 21, 2026, 9:00 a.m. – 12:00 p.m. PT
Session Category: Clinical Research
Session: PO.CL05.12 – Redefining Targeted Therapy: Bispecific T-Cell Engagers and Antibody-Drug Conjugates
Location: Poster Section 48

For more information and to view the Company’s abstract, visit the AACR (Free AACR Whitepaper) Annual Meeting website. The poster will be made available in the Publications section of the Company’s website at the beginning of the poster session.

About CT-202
CT-202 is a Nectin-4 x CD3 TCE bispecific antibody that targets Nectin-4, a cell surface protein that is highly and frequently overexpressed in a variety of solid tumors, including bladder, colorectal, lung and breast. Nectin-4 is a clinically validated target for cancer therapy using a traditional antibody-drug conjugate ("ADC"), but it is also associated with certain adverse events, including neuropathy and rash. CT-202 is a pH-dependent TCE that is designed to be preferentially active within the tumor microenvironment.

(Press release, Context Therapeutics, MAR 19, 2026, View Source [SID1234663776])

On March 19, 2026 Remix Therapeutics (Remix), a clinical-stage biotechnology company developing small molecule therapies to modulate RNA processing and address the underlying drivers of disease, reported that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to first-in-class small molecule MYB mRNA degrader, REM-422, for the treatment of patients with recurrent, metastatic or unresectable adenoid cystic carcinoma (ACC) whose tumors express MYB transcripts containing a poison exon.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"Receiving Fast Track designation for REM-422 underscores the urgent need for new treatment options for patients with ACC," said Peter Smith, PhD, Co-Founder and Chief Executive Officer of Remix Therapeutics. "REM-422 represents a novel approach designed to target MYB, a key oncogenic driver in ACC that has historically been difficult to drug. This designation supports our ongoing efforts to expeditiously advance REM-422 through clinical development to bring this potential therapy to patients as quickly as possible."

REM-422 is a first-in-class, oral small molecule MYB mRNA degrader designed to reduce MYB expression by inducing incorporation of a poison exon in the MYB transcript, leading to degradation of the mRNA and suppression of MYB protein expression. MYB dysregulation is a hallmark driver of ACC and several hematologic malignancies. REM-422 is currently being investigated in the ongoing Phase 1/2 ARIA (A study of REM-422 In Adenoid cystic carcinoma) study, evaluating safety, pharmacokinetics and preliminary anti-tumor activity in patients with recurrent or metastatic, and unresectable ACC.

The FDA’s Fast Track program is designed to accelerate the development and review of drugs that treat serious conditions and address unmet medical needs. The designation for REM-422 was based on positive preliminary results from a Phase 1 clinical trial evaluating REM-422 in patients with recurrent or metastatic ACC. REM-422 is the first oral mRNA degrader of MYB demonstrating proof-of-mechanism and proof-of-concept in ACC along with a favorable safety profile. Anti-tumor activity was observed in patients with recurrent, metastatic or unresectable ACC whose tumors express MYB transcripts containing a poison exon.

About REM-422
REM-422 is a first-in-class, potent, selective, and oral small molecule mRNA degrader that induces the reduction of MYB mRNA and subsequent protein expression. REM-422 functions by facilitating the incorporation of a poison exon in the MYB mRNA transcript, leading to nonsense-mediated decay of the transcript. REM-422 is currently in Phase 1/2 clinical studies in both Adenoid Cystic Carcinoma (ACC) and Acute Myeloid Leukemia (AML) or high-risk myelodysplastic syndrome (HR-MDS). The U.S. Food and Drug Administration granted REM-422 Orphan Drug Designation for ACC and AML and Fast Track designation for ACC.

About the ARIA (A study of REM-422 In Adenoid cystic carcinoma) Clinical Trial
This Phase 1/2, open-label, non-randomized, multicenter study (NCT06118086) is investigating REM-422 in patients with recurrent, metastatic or unresectable Adenoid Cystic Carcinoma (ACC). The study includes a Dose Escalation Phase and a Dose Expansion Phase. The purpose of the Dose Escalation Phase is to determine the maximum tolerated dose and/or recommended Phase 2 dose (RP2D) of REM-422 in patients with recurrent, metastatic, or unresectable ACC. The purpose of Dose Expansion is to further evaluate the safety and anti-tumor activity of the REM-422 RP2D in biomarker positive patients.

About Adenoid Cystic Carcinoma
Adenoid cystic carcinoma (ACC) is a solid tumor that most commonly arises in the salivary glands characterized by frequent recurrent, perineural invasion and dysregulation of the MYB oncogene. Depending on the location of the tumor, symptoms may include numbness of the face, difficulties swallowing, changes in vision, or difficulty breathing, among others. Many therapeutic approaches, such as chemotherapy, kinase inhibitors, and immunotherapy have been studied in ACC with modest or disappointing results, and there remain no approved treatment options.

(Press release, Remix Therapeutics, MAR 19, 2026, View Source [SID1234663775])

On March 19, 2026 Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, reported that new preclinical data highlighting the potential of its highly specific oral PLK1 inhibitor, onvansertib, in combination with trastuzumab deruxtecan (T-DXd) will be presented at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting 2026, taking place April 17-22, 2026 in San Diego, California.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The poster presentation will showcase findings demonstrating that onvansertib enhanced the antitumor activity of T-DXd and reversed resistance in therapy-resistant HER2-low breast cancer models.

Poster Presentation Details:

Title: PLK1 inhibitor onvansertib potentiates the antitumor efficacy of trastuzumab deruxtecan (T-DXd) and reverses its resistance in therapy-resistant HER2-low breast cancer models
Date & Time: April 19, 2026 | 2:00 PM – 5:00 PM PT
Abstract Number: 329
The poster will be made available on the Scientific Publications page of the Company’s website following the presentation.

About Onvansertib
Onvansertib is a highly specific, oral PLK1 inhibitor currently in mid-stage clinical development for RAS-mutated metastatic colorectal cancer. It is also being evaluated in multiple other cancers through investigator-initiated studies, including metastatic pancreatic ductal adenocarcinoma (mPDAC), small cell lung cancer (SCLC), triple-negative breast cancer (TNBC), and chronic myelomonocytic leukemia (CMML).

(Press release, Cardiff Oncology, MAR 19, 2026, View Source [SID1234663774])